Which H is the most important in triple-H therapy for cerebral vasospasm?

Miriam Treggiari, Steven Deem

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To summarize the recent literature of the hemodynamic management of subarachnoid hemorrhage and cerebral vasospasm, also designated as 'triple-H' therapy, and discuss each component of this management approach individually. RECENT FINDINGS: Following the publication of a review on circulatory volume expansion in the Cochrane Registry database in 2004 and a meta-analysis in 2003, there are no new randomized trials of triple-H therapy to prevent or treat cerebral vasospasm. However, physiological studies have been reported that contribute to the understanding of some of the components of triple-H therapy. SUMMARY: There remains a paucity of information regarding the efficacy and safety of triple-H therapy. The complexity in exploring this topic derives not only from the interdependence of the different components of triple-H therapy but also by the limitation in the assessment of hemodynamic variables. However, there is some emerging physiologic data suggesting that normovolemic hypertension may be the component most likely to increase cerebral blood flow after subarachnoid hemorrhage. In contrast, hypervolemic hemodilution is associated with increased complications and might also lower the hemoglobin to excessively low levels.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalCurrent Opinion in Critical Care
Volume15
Issue number2
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Intracranial Vasospasm
Subarachnoid Hemorrhage
Cerebrovascular Circulation
Hemodynamics
Therapeutics
Hemodilution
Registries
Publications
Meta-Analysis
Hemoglobins
Databases
Hypertension
Safety

Keywords

  • Cerebral aneurysm
  • Delayed ischemic neurologic deficit
  • Human
  • Subarachnoid hemorrhage
  • Vasospasm

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Which H is the most important in triple-H therapy for cerebral vasospasm? / Treggiari, Miriam; Deem, Steven.

In: Current Opinion in Critical Care, Vol. 15, No. 2, 04.2009, p. 83-86.

Research output: Contribution to journalArticle

@article{a700ecb28da34e569ad0bbb9506388d3,
title = "Which H is the most important in triple-H therapy for cerebral vasospasm?",
abstract = "PURPOSE OF REVIEW: To summarize the recent literature of the hemodynamic management of subarachnoid hemorrhage and cerebral vasospasm, also designated as 'triple-H' therapy, and discuss each component of this management approach individually. RECENT FINDINGS: Following the publication of a review on circulatory volume expansion in the Cochrane Registry database in 2004 and a meta-analysis in 2003, there are no new randomized trials of triple-H therapy to prevent or treat cerebral vasospasm. However, physiological studies have been reported that contribute to the understanding of some of the components of triple-H therapy. SUMMARY: There remains a paucity of information regarding the efficacy and safety of triple-H therapy. The complexity in exploring this topic derives not only from the interdependence of the different components of triple-H therapy but also by the limitation in the assessment of hemodynamic variables. However, there is some emerging physiologic data suggesting that normovolemic hypertension may be the component most likely to increase cerebral blood flow after subarachnoid hemorrhage. In contrast, hypervolemic hemodilution is associated with increased complications and might also lower the hemoglobin to excessively low levels.",
keywords = "Cerebral aneurysm, Delayed ischemic neurologic deficit, Human, Subarachnoid hemorrhage, Vasospasm",
author = "Miriam Treggiari and Steven Deem",
year = "2009",
month = "4",
doi = "10.1097/MCC.0b013e32832922d1",
language = "English (US)",
volume = "15",
pages = "83--86",
journal = "Current Opinion in Critical Care",
issn = "1070-5295",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Which H is the most important in triple-H therapy for cerebral vasospasm?

AU - Treggiari, Miriam

AU - Deem, Steven

PY - 2009/4

Y1 - 2009/4

N2 - PURPOSE OF REVIEW: To summarize the recent literature of the hemodynamic management of subarachnoid hemorrhage and cerebral vasospasm, also designated as 'triple-H' therapy, and discuss each component of this management approach individually. RECENT FINDINGS: Following the publication of a review on circulatory volume expansion in the Cochrane Registry database in 2004 and a meta-analysis in 2003, there are no new randomized trials of triple-H therapy to prevent or treat cerebral vasospasm. However, physiological studies have been reported that contribute to the understanding of some of the components of triple-H therapy. SUMMARY: There remains a paucity of information regarding the efficacy and safety of triple-H therapy. The complexity in exploring this topic derives not only from the interdependence of the different components of triple-H therapy but also by the limitation in the assessment of hemodynamic variables. However, there is some emerging physiologic data suggesting that normovolemic hypertension may be the component most likely to increase cerebral blood flow after subarachnoid hemorrhage. In contrast, hypervolemic hemodilution is associated with increased complications and might also lower the hemoglobin to excessively low levels.

AB - PURPOSE OF REVIEW: To summarize the recent literature of the hemodynamic management of subarachnoid hemorrhage and cerebral vasospasm, also designated as 'triple-H' therapy, and discuss each component of this management approach individually. RECENT FINDINGS: Following the publication of a review on circulatory volume expansion in the Cochrane Registry database in 2004 and a meta-analysis in 2003, there are no new randomized trials of triple-H therapy to prevent or treat cerebral vasospasm. However, physiological studies have been reported that contribute to the understanding of some of the components of triple-H therapy. SUMMARY: There remains a paucity of information regarding the efficacy and safety of triple-H therapy. The complexity in exploring this topic derives not only from the interdependence of the different components of triple-H therapy but also by the limitation in the assessment of hemodynamic variables. However, there is some emerging physiologic data suggesting that normovolemic hypertension may be the component most likely to increase cerebral blood flow after subarachnoid hemorrhage. In contrast, hypervolemic hemodilution is associated with increased complications and might also lower the hemoglobin to excessively low levels.

KW - Cerebral aneurysm

KW - Delayed ischemic neurologic deficit

KW - Human

KW - Subarachnoid hemorrhage

KW - Vasospasm

UR - http://www.scopus.com/inward/record.url?scp=67749110101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749110101&partnerID=8YFLogxK

U2 - 10.1097/MCC.0b013e32832922d1

DO - 10.1097/MCC.0b013e32832922d1

M3 - Article

VL - 15

SP - 83

EP - 86

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

SN - 1070-5295

IS - 2

ER -